A phase I clinical trial evaluating anti-CD19 CAR-iNKT cells in relapsed/refractory B-cell malignancies has reported encouraging early results, including one complete response and one partial response—both without CRS or GvHD—underscoring the clinical potential of CAR-iNKT cells in overcoming tumor immune escape (NCT03774654). Here, CD19 is linked to neoplasm.